Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C] Olverembatinib ADME study in healthy volunteers
NCT04126707Phase 1Completed
- Sponsor
- Ascentage Pharma
- Start
- Nov 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olverembatinib in chronic myeloid leukemia (CML), sponsored by Ascentage Pharma. Primary endpoints: Radioactivity concentration of each blood and plasma sample, Radioactivity concentration of each urine samples and 2 more. Started Nov 2019; status: completed.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04126707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126707.